David Resnick is a partner and the co-team leader of the Biotechnology/Chemistry team at Nixon Peabody. David assists clients in obtaining and defending intellectual property protection for cutting edge technologies in the life sciences, including stem cells, regenerative medicine and RNAi. David has developed a particular focus on the areas on pharmacogenomics, proteomics, and disease biomarkers and their application in the evolving field of personalized medicine.
David also assists clients by evaluating their intellectual property portfolios, as well as the intellectual property held by competitors or potential acquisitions or partners. In connection with these activities, he has been involved with strategic patent prosecution, due diligence and freedom-to-operate analyses.
David’s clients include many Boston area universities, research hospitals, and life science startups, as well as large pharmaceutical companies.
“Danger, Will Robinson!” These immortal words uttered by the Robot in the 1960s television series “Lost in Space” are now part of our pop culture lexicon when warning of an impending,... Read more »
For months and months, we heard the mantra of “Obama: the change we need; change we can believe in.” The election is finally over. The people have spoken. Now that Senator... Read more »
If you have been following the news in the last month or so, you’ve probably watched in amazement as Congress tackles one of our country’s most pressing issues. I’m not talking... Read more »
It has long been known that different individuals react to the same drug differently. Matching the right therapy with the right individual, commonly know as “personalized medicine,” could improve treatment, reduce... Read more »
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.